TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05856305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorophyllin, Sodium Copper Complex
Description: Additional Chlorophyllin tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Additional Placebo tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
Study: NCT06784986

Intervention type: DEVICE
Group type: OTHER
Intervention: The Conventional Insufflation System
Description: The Conventional Insufflation System employs standard CO2 insufflation techniques for maintaining intra-abdominal pressure during laparoscopic and robotic surgeries. It serves as the base for comparison with the AirSeal® System.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirSeal® System
Description: The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple-lumen filtered tube set, and a valve-free trocar (AirSeal® Access Port). This innovative system allows peritoneal access and pneumoperitoneum maintenance without a mechanical seal, reducing CO2 usage and associated complications.
Study: NCT06783725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Therapy for Insomnia
Description: Mindfulness-based therapy for insomnia (MBTI) is a structured program designed to help individuals with chronic insomnia improve their sleep patterns through mindfulness practices. It combines mindfulness meditation, cognitive behavioral strategies, and sleep education to address the cognitive and physiological factors that disrupt sleep. The therapy emphasizes present-moment awareness, acceptance of sleep difficulties, and the reduction of sleep-related anxiety to promote better sleep quality and overall well-being.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait-list control
Description: The wait-list control group consists of participants who do not receive the intervention during the initial study period but are placed on a waitlist to receive it after the trial concludes. This group serves as a comparison to evaluate the effectiveness of the intervention while ensuring participants eventually have access to the treatment. It helps control for natural changes over time and the psychological effects of expecting future treatment.
Study: NCT06786221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mini-implant template
Description: The proposed structure will be made of three main components: a tooth guide part, a gingival guide part, and a steering part. The tooth guide and gingival guide parts are firmly connected by fracture lines. The mini-implant guide part is specifically designed to accommodate the angle and position required for miniscrew insertion. On the basis of the resin guide plate, add a guide hole structure and change it to simulate the patient's actual tooth root condition.~During usage, the guide can be pre-designed in accordance with the desired planting position and direction of the patient's mini-implant, enabling precise guidance during the implantation process. The designed guide's data is inputted into EnvisionTEC Vida 3D printer to create the mini-implant guide. Prior to the implantation of the mini-screw, patients will be informed about the potential risks and required to sign an informed consent form.
Study: NCT06787209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program to improve lumbopelvic function.
Description: Each individual will receive a weekly session log at the start of the intervention, allowing them to record the total number of sessions performed between in-person visits and the perceived exertion.~In the strengthening phase, both compound and isolated exercises will be performed. These exercises will be of low intensity and maintained for prolonged periods until the patient reaches fatigue or can no longer perform the repetitions correctly. If the patient reaches 40 repetitions, the exercise will be progressed in difficulty. The patient will have one minute of rest after each set.~Each session will include a total of 4 sets focused on the gluteal muscles The speed of execution for each repetition will be between 4-6 seconds. After the strengthening phase, three unilateral static stretches targeting the hip flexors will be performed, each lasting one minute.~The entire program will be performed using bodyweight exercises and adapted exercises that can be done at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: generic health care
Description: The patients will receive 10 physiotherapy sessions at the health center throughout 4 weeks.They will be taught active exercises and undergo passive therapies to address their low back pain. Each session will last approximately 30 minutes.~The intervention will therefore be variable depending on the assigned physiotherapist, as there is no standardized protocol for action.
Study: NCT06786507

Intervention type: DRUG
Intervention: Ustekinumab 90 mg
Description: Ustekinumab is a human monoclonal IgG1 antibody that blocks the p40 subunit of both IL-12 and IL-23 this antagonistic action inhibits the interaction of these cytokines with the IL-12Rβ1 receptor. The IL-12Rβ1 receptor is found on the surface of NK cells and T cells which reduces inflammation and alters the body's immune response

Intervention type: DRUG
Intervention: Infliximab
Description: Infliximab is a biological therapy/immunotherapy medication designed to stimulate the body's immune system and treat certain diseases. Infliximab is a purified, recombinant DNA-derived chimeric IgG monoclonal antibody protein that contains both murine and human components that inhibit tumor necrosis factor-alpha (TNF-α). TNF-α is a signaling protein involved in acute phase reactions and systemic inflammation. Macrophages, CD4+ lymphocytes, NK cells, neutrophils, mast cells, eosinophils, and neurons produce TNF-α. This TNF-α inhibition inhibits the inflammatory reaction's cascade, leading to improved disease condition inflammatory bowel disease
Study: NCT06087601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium chloride
Description: us-guided bilateral genicular nerves sham block with 0,5ml 0,9% normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 95% ethanol
Description: us-guided bilateral genicular nerves neurolysis with 0,5ml 95% ethanol
Study: NCT06007092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPVDC injection level dose 1
Description: patient receive 3 injections of vaccine at the same level dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection level dose 1
Description: patient receive 3 injections of vaccine at the same level dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPVDC injection level dose 2
Description: patient receive 3 injections of vaccine at the same level dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection level dose 2
Description: patient receive 3 injections of vaccine at the same level dose
Study: NCT06426641

Intervention type: DEVICE
Intervention: Polyethylene
Description: There is no intervention

Intervention type: DEVICE
Intervention: Polyethylene
Description: There is no intervention

Intervention type: DEVICE
Intervention: Polyethylene
Description: There is no intervention
Study: NCT05473065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiaxial Prosthetic Foot Emulator
Description: Participants will walk in the laboratory with the multiaxial Prosthetic Foot Emulator (PFE) in three foot modes corresponding to commercial prosthetic study feet. Walking conditions will include self-selected comfortable, slow, and fast speeds, inclines, cross slopes, and uneven terrain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available prosthetic feet
Description: Participants will walk in the laboratory with the commercial prosthetic study feet in three foot modes corresponding to commercial prosthetic study feet. Walking conditions will include self-selected comfortable, slow, and fast speeds, inclines, cross slopes, and uneven terrain.~Additionally, participants will be fit with one of the commercial prosthetic study feet and wear it at home and in the community for approximately one week. Participants will return to the laboratory to follow-up testing, and will complete the community trial with each of the three commercial prosthetic study feet.
Study: NCT05714462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meals consisting of primarily animal protein sources
Description: an omnivorous diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meals consisting of primarily animal protein sources
Description: an omnivorous diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: meals consisting of primarily animal protein sources
Description: an omnivorous diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meals consisting of plant protein sources
Description: an herbivorous diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meals consisting of plant protein sources
Description: an herbivorous diet
Study: NCT06014515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-butanol
Description: Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
Study: NCT04762563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM application
Description: IASTM application .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tape® Tex Gold)
Description: Kinesio Tape® Tex Gold)
Study: NCT06464341

Intervention type: OTHER
Intervention: Observational study no intervention
Description: Observational study no intervention
Study: NCT05127759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: HLX208 450mg bid po
Study: NCT06299826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive low, medium \& high doses of film-coated tablets of AZD5462 OD orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive low, medium \& high doses of film-coated tablets of AZD5462 OD orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive low, medium \& high doses of film-coated tablets of AZD5462 OD orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching doses of film-coated tablets of Placebo OD orally.
Study: NCT04783935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavenclad®
Description: No intervention was administered as a part of this study. Participants who had received Mavenclad® up to 2 years (Year 1 and 2) in the parent study MS700568_0022 (NCT03364036) were enrolled into this extension study and will be assessed up to 2 years follow-up (Year 3 and 4).
Study: NCT06636071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: setrusumab
Description: A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
Study: NCT06636279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gas bubble technique
Description: Inject the sterile air into the anterior chamber after the conventional cataract surgery to reduce corneal endothelial damage
Study: NCT06635057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study: NCT06247215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally tailored resilience-building intervention
Description: A booklist teaching resilience skills for advance care planning discussions
Study: NCT05906537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB410 for injection
Description: SKB410 for injection is administered every 2 weeks (q2w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
Study: NCT05063695

Intervention type: OTHER
Intervention: Multimodal Erector spinae catheter protocol
Description: Patients either received multimodal epidural or ESP protocol
Study: NCT06241937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Clinical Firearm Safety Counseling Training
Description: Members of the DGSOM class of 2027 will participate in a mandatory 3.5 hour training session as a part of the regular curriculum that will include: (1) didactic information on firearm violence epidemiology; (2) suicide epidemiology and introduction to lethal means restriction; (3) firearm safety counseling techniques; (4) a panel of firearm violence survivors / trauma interventionists; and (5) a small group session with discussions of the aforementioned topics and a demonstration of a patient encounter using a standardized patient actor depicting a clinical scenario warranting firearm safety counseling. The training will be taught by faculty members, invited subject matter experts, senior medical students, and the DGSOM Standardized Patient Program.
Study: NCT04987931

Intervention type: DRUG
Intervention: Talazoparib
Description: This retrospective chart review study focuses on patients with HER2- ABC with gBRCA1/2m initiating talazoparib on or after October 16, 2018 and ≥18 years of age at initiation of talazoparib.
Study: NCT05009134

Intervention type: BIOLOGICAL
Intervention: There is no intervention in this study.
Description: There is no intervention in this study.

Intervention type: BIOLOGICAL
Intervention: There is no intervention in this study.
Description: There is no intervention in this study.

Intervention type: BIOLOGICAL
Intervention: There is no intervention in this study.
Description: There is no intervention in this study.
Study: NCT05996822

Intervention type: DRUG
Intervention: ACF injection
Description: AcF injection 1 month after a DXM injection
Study: NCT05518071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRGD-ZW800-1
Description: Intravenous single bolus injection of the targeted NIR fluorophore cRGD-ZW800-1. This targeted 800nm zwitterionic fluorophore developed by the Hospital Pharmacy Department of LUMC consists of the fluorophore ZW800-1 conjugated to the cRGD peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRGD-ZW800-1
Description: Intravenous single bolus injection of the targeted NIR fluorophore cRGD-ZW800-1. This targeted 800nm zwitterionic fluorophore developed by the Hospital Pharmacy Department of LUMC consists of the fluorophore ZW800-1 conjugated to the cRGD peptide
Study: NCT04719845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic laser resection
Description: Laser resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dilatation
Description: Dilatation
Study: NCT06104566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisaftoclax +BTK inhibitor
Description: lisaftolax + BTK inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BTK inhibitor
Description: BTK inhibitor
Study: NCT04835064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Albumin combined with paclitaxel 125mg/m2 intravenous infusion, Day 1, 8, 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion of 1000 mg/m2 was given for more than 30min on days 1, 8, and 15, and repeated every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Oxaliplatin 85 mg/m2 intravenous infusion for 2 h, Day 1;LV 400 mg/m2 intravenous infusion for 2 h, Day 1;Irinotecan 150 mg/m2 was added 30 min after intravenous infusion for 90 min, day 1;This was immediately followed by a continuous intravenous infusion of 5-FU 2400 mg/m2 for 46 h.Repeat every 2 weeks.
Study: NCT04241510

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Description: Kinesio Taping is a special taping method developed by Dr. Kenzo Kase in 1973. This technique triggers natural healing responses of human body by activating nervous and circulatory systems. The tapes are thin, latex-free, cotton, porous and anti-allergenic, with equal thickness of epidermis. It has elastic properites which allows the tape to elongate to %55-60 of its original lenght. Tape can be used up to 1 week even after sweating or cleaning with water. There are different application techniques for different purposes. Facilitation technique facilitates muscle contractions and supports muscle function. Mechancial correction technique is used for joint positioning and correcting motion of muscle-joint dynamics.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Description: Kinesio Taping is a special taping method developed by Dr. Kenzo Kase in 1973. This technique triggers natural healing responses of human body by activating nervous and circulatory systems. The tapes are thin, latex-free, cotton, porous and anti-allergenic, with equal thickness of epidermis. It has elastic properites which allows the tape to elongate to %55-60 of its original lenght. Tape can be used up to 1 week even after sweating or cleaning with water. There are different application techniques for different purposes. Facilitation technique facilitates muscle contractions and supports muscle function. Mechancial correction technique is used for joint positioning and correcting motion of muscle-joint dynamics.
Study: NCT05768529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U16
Description: A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered before U16 treatment.
Study: NCT04828941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Headache Diary
Description: The electronic headache diary is an app-based diary that permits the registration of headaches, their acute treatment and their associated work incapacity. It also permits real-time monitoring of these data.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paper Diary
Description: The paper diary permits the registration of the same variables as the electronic diary in paper format.
Study: NCT05561413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and exercise
Description: The mindfulness and exercise group aims to gradually increase participants exercise levels so that they begin to achieve the recommended levels along with the strengthening exercises for all major muscle groups. Along side this mindfulness will be introduced and built on to help consolidate exercise uptake and help manage symptoms experienced by the participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: The delivery of this practice will be through the app downloaded by participants. The practice based on mindfulness based stress reduction (MBSR). Will build on practice over the 8 weeks.
Study: NCT01829009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Group
Description: An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24
Study: NCT06485895

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: test IGRA
Description: BLOOD SAMPLES

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TEST QUATIFERON TB Gold Plus
Description: BLOOD SAMPLES
Study: NCT05063084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optiflow - HFNO
Description: Pre-oxygenation: HFNO with a 2 L/Kg/min flow during 2 min with 100% FiO2 Oxygenation: during the tracheal intubation, HFNO with a 2 L/Kg/min flow during 2 min with 100% FiO2

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Classic
Description: Pre-oxygenation: with facemask during 2 min with 100% FiO2, flow 6 to 8L/min. No oxygenation during the tracheal intubation
Study: NCT05825963

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: The participants select hamburgers randomly by themselves, with or without (control) 12 g of psyllium, each containing 85 g of hamburger bread, 160 g of 20% fat beef, 2.56 g of salt, and 1.28 g of pepper, and asked to consume them with 200 ml of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: The participants select hamburgers randomly by themselves, with or without (control) 12 g of psyllium, each containing 85 g of hamburger bread, 160 g of 20% fat beef, 2.56 g of salt, and 1.28 g of pepper, and asked to consume them with 200 ml of water.
Study: NCT05846568

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR1801
Description: The injection solution GR1801 does not contain preservatives. The excipients include histidine/histidine hydrochloride (20mM), trehalose (90 mg/mL), disodium EDTA (0.372mg/mL) and polysorbate 80 (0.5 mg/mL). The pH value is 5.8 and each bottle contains 2mg of GR1801 protein. The packaging material is a borosilicate glass tube injection bottle (2mL) with a halogenated butyl rubber stopper for injection and an aluminum-plastic composite cap for antibiotic bottles.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Rabies Immunoglobulin(HRIG)
Description: The HRIG is a Chinese licensed Human Rabies Immunoglobulin produced by BOYA-BIO, which are derived from human plasma, and then purified and filled in the injectable vial form.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Vaccine
Description: The Chinese licensed freeze-dried rabies vaccine produced by CHENGDA PHARMACEUTICALS for human use (Vero Cells) which is indicated for the rabies Post-exposure Prophylaxis (PEP) .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies Vaccine
Description: The Chinese licensed freeze-dried rabies vaccine produced by CHENGDA PHARMACEUTICALS for human use (Vero Cells) which is indicated for the rabies Post-exposure Prophylaxis (PEP) .